MF
HRTX icon

Magnetar Financial’s Heron Therapeutics HRTX Stock Holding History

Magnetar Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-183,267
Closed -$1.05M – 1741
2022
Q1 		$1.05M Buy
183,267
+18,192
+11% +$133K 0.01% 785
2021
Q4 		$1.51M Buy
165,075
+7,113
+5% +$72.6K 0.02% 732
2021
Q3 		$1.69M Buy
+157,962
New +$1.92M 0.02% 628

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Magnetar Financial's HRTX Position: Q2 2022 in Review

Magnetar Financial sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 183,267 shares — an estimated $1.05M sold.

Magnetar Financial first reported a position in HRTX in Q3 2021 and held it in 3 quarters. The position peaked at $1.69M in Q3 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Magnetar Financial reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Magnetar Financial sold 183,267 Heron Therapeutics shares in Q2 2022, an estimated $1.05M.
  • Magnetar Financial first reported a position in Heron Therapeutics in Q3 2021 and held it in 3 quarters.
  • Magnetar Financial's Heron Therapeutics position peaked at $1.69M in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Magnetar Financial's 13F filing for Q2 2022, filed 15 Aug 2022.